USE OF AZABICYCLO HEXANE DERIVATIVES
    1.
    发明申请
    USE OF AZABICYCLO HEXANE DERIVATIVES 审中-公开
    使用异丁醇衍生物衍生物

    公开(公告)号:US20120196910A1

    公开(公告)日:2012-08-02

    申请号:US13432359

    申请日:2012-03-28

    CPC分类号: A61K31/403

    摘要: The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome.

    摘要翻译: 本发明提供了式(I)化合物或其药学上可接受的盐或溶剂化物盐的新用途:用于治疗躯体畸形障碍或高钙血症,躯体畸形障碍,神经性贪食症,神经性厌食症,暴饮暴食症,paraphilia 和非同性恋性成瘾,Sydeham的舞蹈病,斜颈,自闭症,运动障碍,包括图雷特综合征。

    Use of Azabicyclo Hexane Derivatives
    2.
    发明申请
    Use of Azabicyclo Hexane Derivatives 审中-公开
    氮杂双环己烷衍生物的应用

    公开(公告)号:US20090036461A1

    公开(公告)日:2009-02-05

    申请号:US12064119

    申请日:2006-08-21

    CPC分类号: A61K31/403

    摘要: The present invention provides a new use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate salt thereof: wherein: G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxyl, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3I s C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; in the manufacture of a medicament for the treatment of a somatoform disorder such as body dysmorphic disorder or hyperchondriasis, bulimia nervosa, anorexia nervosa, binge eating, paraphilia and nonparaphilic sexual addictions, Sydeham's chorea, torticollis, autism, a movement disorder including Tourette's syndrome; and in the manufacture of a medicament for the treatment of premature ejaculation.

    摘要翻译: 本发明提供式(I)化合物或其药学上可接受的盐或溶剂合物盐的新用途:其中:G选自:苯基,吡啶基,苯并噻唑基,吲唑基; p为0〜5的整数。 R 1独立地选自:卤素,羟基,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,卤代C 1-4烷氧基,C 1-4烷酰基; 或对应于R5组; R2是氢或C1-4烷基; R3I的C1-4烷基; R 4是氢或苯基,杂环基,5或6元杂芳族基团或8至11元双环基团,其中任何基团任选被1,2,3或4个取代基取代 选自:卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,C 1-4烷酰基; R5是选自以下的部分:异恶唑基,-CH 2 -N-吡咯基,1,1-二氧化-2-异噻唑烷基,噻吩基,噻唑基,吡啶基,2-吡咯烷酮基,任选地被一个或多个 选自以下的两个取代基:卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,C 1-4烷酰基; 当R1为氯且p为1时,该R1不存在于与分子的其余部分的连接键的邻位; 当R1对应于R5时,p为1; 在制备用于治疗躯体畸形障碍或高钙血症,贪食神经性神经性,神经性厌食症,暴饮暴食和非耻辱性性成瘾症,Sydeham氏舞蹈病,斜颈,自闭症,包括图雷特综合征的运动障碍的药物中的药物。 以及制备用于治疗早泄的药物。

    Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
    3.
    发明授权
    Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors 失效
    可用作多巴胺D3受体调节剂的氮杂双环(3.1.0)己烷衍生物

    公开(公告)号:US07875643B2

    公开(公告)日:2011-01-25

    申请号:US11911229

    申请日:2006-04-13

    IPC分类号: A61K31/41 C07D249/08

    CPC分类号: C07D403/12

    摘要: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R5; each R2 is independently hydrogen or C1-4alkyl; n is 2, 3, 4 or 5; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl and SF5; R5 is selected from a group consisting of: isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl and 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; and when R1 corresponds to R5, p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

    摘要翻译: 本发明涉及新的式(I)化合物或其药学上可接受的盐:其中G选自:苯基,吡啶基,苯并噻唑基和吲唑基; p为0〜5的整数。 R 1独立地选自:卤素,羟基,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,卤代C 1-4烷氧基,C 1-4烷酰基和SF 5; 或对应于R5组; 每个R 2独立地是氢或C 1-4烷基; n为2,3,4或5; R3是C1-4烷基; R 4是氢或苯基,杂环基,5或6元杂芳族基团或8至11元双环基团,其中任何基团任选被1,2,3或4个取代基取代 选自卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,C 1-4烷酰基和SF 5; R5选自:异恶唑基,-CH2-N-吡咯基,1,1-二氧化-2-异噻唑烷基,噻吩基,噻唑基,吡啶基和2-吡咯烷基,并且该基团任选被一个或两个取代基取代 选自:卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基和C 1-4烷酰基; 当R1对应于R5时,p为1; 它们的制备方法,这些方法中使用的中间体,含有它们的药物组合物及其在治疗中的用途,作为多巴胺D3受体的调节剂。 治疗药物依赖性,作为抗精神病药,治疗强迫性强迫症,早泄或认知障碍。

    Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors
    4.
    发明授权
    Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors 失效
    氮杂双环[3.1.0]己基苯基衍生物作为多巴胺D3受体的调节剂

    公开(公告)号:US07776904B2

    公开(公告)日:2010-08-17

    申请号:US12064121

    申请日:2006-08-18

    IPC分类号: A61K31/403 C07D209/52

    CPC分类号: C07D209/52

    摘要: The present invention relates to novel compounds of formula (IA) or a salt thereof: wherein: A is attached to the phenyl group at the meta position or the para position relative to the cyclopropyl group, and is selected from the group consisting of: —SO2NR5—, —SO2CR2R3—, —CR2R3SO2— and —NR5SO2—; R1 is hydrogen, C1-6alkyl, haloC1-6alkyl or C2-6alkylene; R2 and R3 are independently hydrogen or C1-6alkyl; R4 is hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; R5 is hydrogen, C1-6alkyl, or a phenyl optionally substituted by R4; and R6 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat substance related disorders, as antipsychotic agents premature ejaculation or cognition impairment.

    摘要翻译: 本发明涉及新的式(IA)化合物或其盐:其中:A相对于环丙基在间位或对位与苯基连接,并且选自: - SO 2 NR 5 - , - SO 2 CR 2 R 3 - , - CR 2 R 3 SO 2 - 和-NR 5 SO 2 - ; R1是氢,C1-6烷基,卤代C 1-6烷基或C 2-6亚烷基; R2和R3独立地是氢或C1-6烷基; R 4是氢,卤素,C 1-6烷基,卤代C 1-6烷基,C 1-6烷氧基或卤代C 1-6烷氧基; R5是氢,C1-6烷基或任选被R4取代的苯基; 并且R 6是氢,C 1-6烷基,卤代C 1-6烷基,C 1-6烷氧基或卤代C 1-6烷氧基; 它们的制备方法,这些方法中使用的中间体,含有它们的药物组合物及其在治疗中的用途,作为多巴胺D3受体的调节剂。 治疗物质相关疾病,作为抗精神病药物早泄或认知障碍。

    Compounds having activity at 5ht2c receptor and uses thereof

    公开(公告)号:US20070191457A1

    公开(公告)日:2007-08-16

    申请号:US10551904

    申请日:2004-04-05

    IPC分类号: A61K31/454 C07D401/02

    CPC分类号: C07D209/46

    摘要: Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, —COOR3, —COR4, wherein R3 and R4 are independently hydrogen or C1-6alkyl, or —COR5, wherein R5 is amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; p is 0, 1, 2 or 3; Q is a 6-membered aromatic group or a 6-membered heteroaromatic group; A is —(CH2—CH2)—, —(CH═CH)—, or a group —(CHR7)— wherein R7 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, —CH2— or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, —CH2—, —(CH2)2— or —CH═CH—; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is —NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, such as for depression or anxiety, are also disclosed.

    3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands
    8.
    发明授权
    3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands 失效
    3-三唑基硫杂烷基-3-氮杂双环(3-1-O)己烷及其作为多巴胺D3受体配体的用途

    公开(公告)号:US07803820B2

    公开(公告)日:2010-09-28

    申请号:US11911035

    申请日:2006-04-12

    CPC分类号: C07D413/12 C07D403/12

    摘要: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is hydrogen or C1-4alkyl; R2 is C1-4alkyl; R3 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl and SF5; p is 0, 1, 2, 3 or 4; and R4 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy and C1-4alkanoyl; n is 0 or 1; wherein when R4 is chlorine and p is 1, such R4 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and wherein, if n is 0, R3 comprises at least one SF5 group as a substituent; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

    摘要翻译: 本发明涉及新的式(I)化合物或其药学上可接受的盐:其中R 1是氢或C 1-4烷基; R2是C1-4烷基; R 3为氢或苯基,杂环基,5或6元杂芳族基团或8至11元双环基团,其中任何基团任选被1,2,3或4个取代基取代 选自卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,C 1-4烷酰基和SF 5; p是0,1,2,3或4; R 4独立地选自:卤素,羟基,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,卤代C 1-4烷氧基和C 1-4烷酰基; n为0或1; 其中当R 4为氯并且p为1时,相对于与分子的其余部分的连接键,该R 4不存在于邻位; 并且其中,如果n为0,则R 3包含至少一个SF 5基团作为取代基; 它们的制备方法,这些方法中使用的中间体,含有它们的药物组合物及其在治疗中的用途,作为多巴胺D3受体的调节剂。 治疗药物依赖性,作为抗精神病药,治疗强迫性强迫症,早泄或认知障碍。

    3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands
    10.
    发明申请
    3-Triazolylthiaalkyl-3-Azabicyclo (3-1-O) Hexanes and Their Use as Dopamine D3 Receptor Ligands 失效
    3-三唑基硫杂烷基-3-氮杂双环(3-1-O)己烷及其作为多巴胺D3受体配体的用途

    公开(公告)号:US20080176917A1

    公开(公告)日:2008-07-24

    申请号:US11911035

    申请日:2006-04-12

    CPC分类号: C07D413/12 C07D403/12

    摘要: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 is hydrogen or C1-4alkyl; R2 is C1-4alkyl; R3 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl and SF5; p is 0, 1, 2, 3 or 4; and R4 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy and C1-4alkanoyl; n is 0 or 1; wherein when R4 is chlorine and p is 1, such R4 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and wherein, if n is 0, R3 comprises at least one SF5 group as a substituent; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.

    摘要翻译: 本发明涉及新的式(I)化合物或其药学上可接受的盐:其中R 1是氢或C 1-4烷基; R 2是C 1-4烷基; R 3是氢或苯基,杂环基,5或6元杂芳族基团或8至11元双环基团,其中任何基团任选被 1,2,3或4个选自以下的取代基:卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1 -4个烷氧基,C 1-4烷酰基和SF 5; p是0,1,2,3或4; R 4和R 4独立地选自:卤素,羟基,氰基,C 1-4烷基,卤代C 1-4烷基 C 1-4烷氧基,卤代C 1-4烷氧基和C 1-4烷酰基; n为0或1; 其中当R 4为氯且p为1时,相对于与分子其余部分的连接键,该R 4不在邻位; 并且其中,如果n为0,则R 3 3包含至少一个SF 5基团作为取代基; 其制备方法,这些方法中使用的中间体,含有它们的药物组合物及其在治疗中的用途,作为多巴胺D 3受体的调节剂,例如。 治疗药物依赖性,作为抗精神病药,治疗强迫性强迫症,早泄或认知障碍。